Organotypic Retinal Explant Cultures from Macaque Monkey

Summary

Retinal explants obtained from wild-type macaques were cultured in vitro. Retinal degeneration and the cGMP-PKG signaling pathway was induced using the PDE6 inhibitor zaprinast. cGMP accumulation in the explants at different zaprinast concentrations was verified using immunofluorescence.

Abstract

Hereditary retinal degeneration (RD) is characterized by progressive photoreceptor cell death. Overactivation of the cyclic guanosine monophosphate (cGMP)-dependent protein kinase (PKG) pathway in photoreceptor cells causes photoreceptor cell death, especially in models harboring phosphodiesterase 6b (PDE6b) mutations. Previous studies on RD have used mainly murine models such as rd1 or rd10 mice. Given the genetic and physiological differences between mice and humans, it is important to understand to which extent the retinas of primates and rodents are comparable. Macaques share a high level of genetic similarity with humans. Therefore, wild-type macaques (aged 1-3 years) were selected for the in vitro culture of retinal explants that included the retina-retinal pigment epithelium (RPE)-choroid complex. These explants were treated with different concentrations of the PDE6 inhibitor zaprinast to induce the cGMP-PKG signaling pathway and simulate RD pathogenesis. cGMP accumulation and cell death in primate retinal explants were subsequently verified using immunofluorescence and the TUNEL assay. The primate retinal model established in this study may serve for relevant and effective studies into the mechanisms of cGMP-PKG-dependent RD, as well as for the development of future treatment approaches.

Introduction

Hereditary retinal degeneration (RD) is characterized by progressive photoreceptor cell death and is caused by mutations in a wide variety of pathogenic genes¹. The end result of RD is vision loss and in the vast majority of cases the disease remains untreatable to this day. Therefore, it is important to study the cellular mechanisms leading to photoreceptor death using models that faithfully represent the human disease condition. Here, primate-based models are of particular interest due to their closeness to humans. Notably, such models may advance the development of appropriate therapeutic interventions that can halt or delay photoreceptor cell death.

Previous research on the mechanisms of cell death in RD has demonstrated that the decrease or loss of phosphodiesterase 6 (PDE6) activity caused by RD-triggering gene mutations leads to reduced hydrolysis of cyclic guanosine monophosphate (cGMP)^2,3. cGMP is a specific agonist of the cyclic nucleotide-gated ion channels (CNGCs) in the rod outer segments (ROSs) and is also a key molecule responsible for the conversion of light signals into electrical signals in vertebrate photoreceptor cells⁴. Reduced cGMP hydrolysis causes the accumulation of cGMP in ROSs, leading to the opening of CNGCs ⁵. Consequently, the phototransduction pathways are activated, resulting in an increase in cation concentrations in photoreceptor cells. This process imposes a metabolic burden on photoreceptors, which when overactivated, for instance, by mutations in PDE6, may cause cell death.

Many studies have shown that a significant overaccumulation of cGMP in photoreceptors of mouse models with different RD gene mutations may cause the activation of cGMP-dependent protein kinase (PKG)^3,6. This leads to a substantial increase in dying, TUNEL-positive cells and a gradual thinning of the photoreceptor cell layer. Previous studies suggest that PKG overactivation caused by elevated cGMP levels is a necessary and sufficient condition for the induction of photoreceptor cell death^2,5. Studies on different mouse models of RD have also shown that PKG activation induced by elevated cGMP levels in photoreceptors, leads to overactivation of downstream effectors such as poly-ADP-ribose polymerase 1 (PARP1), histone deacetylase (HDAC), and calpain^2,7,8,9. This implies causal associations between these different target proteins and photoreceptor cell death.

However, previous research on the pathology, toxicopharmacology, and therapy of RD was mainly based on mouse models for RD^10,11,12. Nevertheless, immense difficulties remain in the clinical translation of these results. This is owing to the considerable genetic and physiological differences between mice and humans, especially with respect to the retinal structure. In contrast, non-human primates (NHPs) also share a high degree of similarity with humans with respect to genetic characteristics, physiological patterns, and environmental factor regulation. For example, optogenetic therapy was investigated as a means to restore retinal activity in an NHP model¹³. Lingam and colleagues demonstrated that good manufacturing practice-grade human-induced pluripotent stem cell-derived retinal photoreceptor precursor cells may rescue cone photoreceptor damage in NHP¹⁴. Therefore, NHP models are important for the exploration of RD pathogenesis and the development of effective treatment methods. In particular, NHP models of RD, exhibiting pathogenic mechanisms similar to those in humans, could play a critical role in studies on the development and in vivo toxicopharmacology analysis of new drugs.

In view of the long life-cycle, high level of technical difficulties, and high cost involved in establishing in vivo primate models, we established an in vitro non-human primate (NHP) model using cultures of explanted macaque retina. First, wild-type macaques aged 1-3 years were selected for in vitro culture of retinal explants, which included the retina-RPE-choroid complex. Explants were then treated with different concentrations of the PDE6 inhibitor zaprinast (100 µM, 200 µM, and 400 µM) to induce the cGMP-PKG signaling pathway. Photoreceptor cell death was quantified and analyzed using the TUNEL assay, and cGMP accumulation in explants was verified via immunofluorescence. Given the high degree of similarity with respect to cell distribution and morphology, retinal layer thickness, and other physiological characteristics of the retina between monkeys and humans, the establishment of the cGMP-PKG signaling pathway in the in vitro retinal model may facilitate future research on the pathogenesis of RD as well as studies into the development and toxicopharmacology of new drugs for RD treatment.

Protocol

The animal study was reviewed and approved by the Ethics Review Committee of Institute of Zoology, Chinese Academy of Sciences (IACUC-PE-2022-06-002), and animal ethics review and animal protocol of Yunnan University (YNU20220149).

1. Preparation of retinal explants

1. Obtain primate eyeballs from wild-type macaques, aged 1 to 3 years old, store in tissue storage solution, and transport on ice within 3 h of enucleation after the monkeys were sacrificed or after natural death.
2. For the preparation of proteinase K solution, dissolve 25 mg of proteinase K in 250 µL of distilled water, and then add 225 µL of the solution to 18.5 mL of basal medium (R16).
3. Wash the eyeballs in 10 mL of 5% povidone-iodine (povidone-iodine: water = 1:19) for 30 s and dip them into 5% penicillin/streptomycin (PEN/STREP):phosphate-buffered saline = 1:19 for 1 min to avoid bacterial contamination. Then, incubate the eyeballs in 10 mL of R16 medium for 5 min.
4. Pre-heat the proteinase K solution in a 37 °C incubator. Then, immerse the eyeballs in 10 mL of proteinase K solution and incubate for 2 min. Immerse the eyeballs in 10 mL of R16 + fetal bovine serum (1:1) solution, incubate for 5 min, and then transfer the eyeballs to 10 mL of fresh R16 for a final wash.
5. Separate out the sclera, cornea, iris, lens, and vitreous body, and cut the retina from 4 sides with tweezers and scissors (Figure 1A-L).
6. Cut retinal explants with trephine blades into five sections-a 4 mm trephine blade for the nasal/temporal/superior/inferior side and a 6 mm trephine blade for the central side (containing optic disk and macula; Figure 1M-O). Cut at the following distance from the optic nerve head: 1.5 mm for nasal, 4 mm for temporal, and 2 mm for both superior and inferior side.
7. Transfer the retina explants (containing retina and choroid) with eyelid depressor and place them in the middle of the insert, photoreceptor side up (Figure 1P). Place approximately 1 mL of complete medium (R16 supplemented with BSA, transferrin, progesterone, insulin, T3, corticosterone, vitamin B1, vitamin B12, retinol, retinyl acetate, DL-tocopherol, tocopheryl acetate, linoleic acid, L-cysteine HCl, glutathione, glutamine, vitamin C) below the membrane on the plate to fully cover the retina.

2. Primate retinal explant culture

1. Culture retinal explants in complete medium and place in a 37 °C incubator aerated with humidified 5% CO₂.
2. Apply drug treatment at appropriate concentration to the retinal culture medium (e.g., zaprinast at concentrations of 100 µM, 200 µM, or 400 µM). Use at least three explants per treatment condition and use explants without drug as control. Treat with drug for 4 days.

3. Fixing and cryo-sectioning

1. Incubate retinal explants with 1 mL of paraformaldehyde (PFA) for 45 min, rinse them briefly with 1 mL of phosphate-buffered saline (PBS), and then incubate with 10% sucrose for 10 min, 20% sucrose for 20 min, and 30% sucrose for 30 min (1 mL for each retina explant).
2. Cut retinal explants using trephine blades to ensure consistency in the size of the explants obtained from different sites with the following characteristics: four quadrants in the periphery, 6 mm at the center. Then, transfer the retinal explants into a tinbox (about 1.5 cm x 1.5 cm x 1.5 cm) with O.C.T. embedding medium to cover the tissue. Immediately, freeze the tissue sections in liquid nitrogen and place in a -20 °C refrigerator for storage.
3. Use a sharp blade to trim the agar into a small block containing the tissue sample, cut the sample blocks into 10 µm sections, and place them on adhesion microscope slides using a soft brush. Then, dry for 45 min at 40 °C and store at -20 °C until use.

4. Immunohistochemistry (Figure 2)

1. cGMP staining
   1. Dry the slides and draw a hydrophobic ring around the retinal sections with a liquid blocker pen to cover the samples.
   2. Immerse slides in 200 µL of 0.3% phosphate buffer saline and Triton X-100 per slide (PBST) for 10 min at room temperature, and then in blocking solution (5% normal donkey serum, 0.3% PBST, 1% BSA, 200 µL per slide) for 1 h at room temperature.
   3. Incubate the samples overnight with the primary antibody (1:250, sheep anti-cGMP, 200 µL per slide) prepared in the blocking solution at 4 °C, and then rinse with PBS for 10 min (200 µL per slide) 3x.
   4. Incubate the samples with secondary antibody (1:300, Donkey anti sheep Alxea Fluor 488, 200 µL per slide) for 1 h at room temperature, and then rinse with PBS for 10 min, 3x. Cover the samples with an antifade mounting medium containing 4',6-diamidino-2-phenylindole (DAPI), and store at 4 °C for at least 30 min before imaging.
2. TUNEL staining
   1. Dry the slides at room temperature for 15 min and draw a water-repellent barrier ring around retinal tissue specimens with the liquid blocker pen, and then incubate them in 40 mL of PBS for 15 min.
   2. Incubate slides in 42 mL (per five slides) of TBS (0.05 M Tris-buffer) at 37 °C. Aspirate out the TBS, and incubate the samples with 6 µL of proteinase K for 5 min. Then, wash slides 3x with TBS for 5 min each time.
   3. Expose the slides to 40 mL of ethanol-acetic acid solution in the choplin, cover with a transparent sheet, and incubate at -20 °C for 5 min. Wash the slides 3x with TBS for 5 min each time.
   4. Expose the slides to blocking solution (1% BSA; 200-300 µL per slide as per requirement) and incubate in a humidity chamber for 1 h.
   5. Prepare TUNEL kit solution, TMR red, in the following proportion: 62.50 µL of blocking solution (1% BSA), 56.25 µL of labeling solution (TMR-dUTP), and 6.25 µL of the enzyme (proportion for each slide). Add approximately 130 µL of this solution per slide and incubate at 37 °C for 1 h. Then, wash the slides with PBS for 5 min (200 µL per slide), 2x.
   6. Place cover slides containing 1-2 drops of antifade mounting medium with DAPI over the samples, and then incubate the slides at 4 °C for at least 30 min before imaging.
3. cGMP staining combined with TUNEL staining
   1. cGMP staining was followed by TUNEL staining. Follow the steps of TUNEL staining from step 4.2.1 to step 4.2.5, and then continue the steps of cGMP staining from step 4.1.2 to step 4.1.4.
4. Perform light and fluorescence microscopy with camera parameters as follows: exposure time = 125 ms, ROI size = 2752 x 2208, Color = B/M. Capture images using the software. Picture four different fields with a digital camera at 20x magnification from each section and obtain representative pictures from the central areas of the retina using DAPI (465 nm), EGFP (509 nm), TMP (578 nm), with Z-Stack scanning having an interval = 1 µm and optional = 1.251 µm.

Results

In this study, Macaque monkey retinal explant culture was performed using explants containing the retina-RPE-choroid complex (Figure 1, Supplementary Figure S1). Compared with the in vitro culture of retinal cells using the retina without the attached RPE and choroid, our explant culture facilitates better cell survival and accordingly, prolongs the survival of photoreceptor cells.

We used different concentrations of the PDE6 inhibitor za...

Discussion

Visual phototransduction refers to the biological process by which light signals are converted to electrical signals by photoreceptor cells within the retina of the eye. Photoreceptor cells are polarized neurons capable of phototransduction, and there are two different types of photoreceptors termed rods and cones after the shapes of their outer segments. Rods are responsible for the scotopic vision and cones are responsible for photopic and high acuity vision. Hereditary RD relates to neurodegenerative diseases characte...

Materials

Name	Company	Catalog Number	Comments
Bovine Serum Albumin (BSA)	Sigma	B2064	Blocking solution
Corticosterone	Sigma	C2505	Supplements of Complete Medium
DL-tocopherol	Sigma	T1539	Supplements of Complete Medium
Donkey anti sheep, Alxea Fluor 488	Life technologies corporation	A11015	Secondary antibody of cGMP
Ethanol-acetic acid solution	Shyuanye	R20492	Fixing liquid
Fetal Bovine Serum	Gemini	900-108	Blocking solution
Fluorescence microscope	Carl Zeiss	Axio Imager.M2	Immunofluorescence imaging
Glutamine	Sigma	G8540	Supplements of Complete Medium
Glutathione	Sigma	G6013	Supplements of Complete Medium
In Situ Cell Death Detection Kit, TMR red	Roche	12156792910	TUNEL assay
Insulin	Sigma	16634	Supplements of Complete Medium
L-cysteine HCl	Sigma	C7477	Supplements of Complete Medium
Linoleic acid	Sigma	L1012	Supplements of Complete Medium
MACS Tissue Storage Solution	Miltenyi	130-100-008	Optimized storage of fresh organ and tissue samples
Normal Donkey Serum	Solarbio	SL050	Blocking solution
Paraformaldehyde(PFA)	Biosharp	BL539A	Fixing agent
PEN. / STREP. 100×	Millipore	TMS-AB2-C	Penicillin / Streptomycin antibiotics
Phosphate buffer saline(PBS)	Solarbio	P1010	Buffer solution
Povidone-iodine	Shanghailikang	310411	Disinfector agent
Progesterone	Sigma	P8783	Supplements of Complete Medium
Proteinase K	Millpore	539480	Break down protein
R16 medium	Life technologies corporation	074-90743A	Basic medium
Retinol	Sigma	R7632	Supplements of Complete Medium
Retinyl acetate	Sigma	R7882	Supplements of Complete Medium
Sheep anti-cGMP	Jan de Vente, Maastricht University, the Netherlands		Primary antibody of cGMP
Sucrose	GHTECH	57-50-1	Dehydrating agent
T3	Sigma	T6397	Supplements of Complete Medium
Tissue-Tek medium (O.C.T. Compound)	SAKURA	4583	Embedding medium
Tocopheryl acetate	Sigma	T1157	Supplements of Complete Medium
Transferrin	Sigma	T1283	Supplements of Complete Medium
Transwell	Corning Incorporated	3412	Cell / tissue culture
Tris-buffer (TBS)	Solarbio	T1080	Blocking buffer
Triton X-100	Solarbio	9002-93-1	Surface active agent
VECTASHIELD Medium with DAPI	Vector	H-1200	Mounting medium
Vitamin B1	Sigma	T1270	Supplements of Complete Medium
Vitamin B12	Sigma	V6629	Supplements of Complete Medium
Vitamin C	Sigma	A4034	Supplements of Complete Medium
Zaprinast	Sigma	Z0878	PDE6 inhibitor
Zeiss Imager M2 Microscope	Zeiss, Oberkochen,Germany		upright microscope
LSM 900 Airyscan			high resolution laser scanning microscope
Zeiss Axiocam	Zeiss, Oberkochen,Germany		digital camera
Zeiss Axiovision4.7
Adobe
Illustrator CC 2021 (Adobe Systems Incorporated, San Jose, CA)
Primate eyeballs from wildtype macaque	KUNMING INSTITUTE OF ZOOLOGY	SYXK () K2017 -0008
Super Pap Pen Pen (Liquid Blocker, Diado, 0010, Japan
TUNEL kit solution (REF12156792910, Roche,Germany),